Dr. Alex Zhavoronkov will conduct a deep-dive analysis of Insilico Medicine’s unique, differentiated path to breaking through industry bottlenecks. (IMAGE)

InSilico Medicine

Dr. Alex Zhavoronkov will conduct a deep-dive analysis of Insilico Medicine’s unique, differentiated path to breaking through industry bottlenecks.

Caption

He will showcase how Insilico leverages its proprietary triad—the end-to-end Pharma.AI platform, the MMAI Gym specialized training and benchmarking framework, and the fully automated Robotic Chemistry and Biology Laboratory—to reshape the fundamental logic of R&D, bypass prohibitive entry barriers, and achieve agile translation and closed-loop validation "from algorithm to clinical." Together with ecological partners, Insilico aims to embark on a new journey of AI-driven life sciences.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.